ZURICH, Sept 20 (Reuters) - Actelion Ltd (ATLN.VX), has been asked to hand over documents related to the marketing and sales practices of its key drug Tracleer in the United States, the Swiss biotech giant said on Monday.
The group said it had received a subpoena from the United States Attorney's Office for the Northern District of California and that it would cooperate with the investigation.
A spokesman for the group said Actelion had no further information as to why it had received the subpoena.
Tracleer is a prescription medication to treat pulmonary arterial hypertension, a rare heart and lung disorder. Tracleer brings in more than $1 billion a year. (Reporting by Katie Reid; Editing by Jon Loades-Carter)
Monday, September 20, 2010
Actelion to hand over Tracleer documents in U.S. | Reuters
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment